Literature DB >> 25852977

Use of ketamine in acute cases of suicidality.

Jae Lee1, Puneet Narang1, Manasa Enja1, Steven Lippmann1.   

Abstract

Ketamine is an N-methyl-D- aspartate antagonist with rapid antidepressant effects. Research shows that ketamine has a fast onset of reduction in depressive symptoms and shows sustained remission of suicidal ideation in some patients. This article provides a brief review of the literature on the use of ketamine for depression and in acute cases of suicidality. The authors conclude that, while further investigation is needed, ketamine may be a useful treatment option for acute suicidality in emergency room settings.

Entities:  

Keywords:  Ketamine; emergency room; suicidal behavior; suicidal ideation; suicidal prevention; suicidality

Year:  2015        PMID: 25852977      PMCID: PMC4382138     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  20 in total

1.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

2.  Ketamine abusers presenting to the emergency department: a case series.

Authors:  A L Weiner; L Vieira; C A McKay; M J Bayer
Journal:  J Emerg Med       Date:  2000-05       Impact factor: 1.484

3.  Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers.

Authors:  Ping Qin; Merete Nordentoft
Journal:  Arch Gen Psychiatry       Date:  2005-04

4.  Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany.

Authors:  Robert M Post; Gabriele S Leverich; Lori L Altshuler; Mark A Frye; Trisha Suppes; Paul E Keck; Susan L McElroy; Willem A Nolen; Ralph Kupka; Heinz Grunze; Joerg Walden; Mike Rowe
Journal:  Int Clin Psychopharmacol       Date:  2011-03       Impact factor: 1.659

5.  Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy.

Authors:  Harold W Goforth; Tracey Holsinger
Journal:  J ECT       Date:  2007-03       Impact factor: 3.635

6.  Mechanism of action of ketamine.

Authors:  Stephen M Stahl
Journal:  CNS Spectr       Date:  2013-08       Impact factor: 3.790

Review 7.  Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2008-06       Impact factor: 4.384

8.  Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.

Authors:  Rebecca B Price; Dan V Iosifescu; James W Murrough; Lee C Chang; Rayan K Al Jurdi; Syed Z Iqbal; Laili Soleimani; Dennis S Charney; Alexandra L Foulkes; Sanjay J Mathew
Journal:  Depress Anxiety       Date:  2014-03-25       Impact factor: 6.505

Review 9.  Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy.

Authors:  Caroline Caddy; Giovanni Giaroli; Thomas P White; Sukhwinder S Shergill; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2014-04

10.  Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.

Authors:  Peter R Diamond; Andrew D Farmery; Stephanie Atkinson; Jag Haldar; Nicola Williams; Phil J Cowen; John R Geddes; Rupert McShane
Journal:  J Psychopharmacol       Date:  2014-04-03       Impact factor: 4.153

View more
  6 in total

Review 1.  Understanding epigenetic architecture of suicide neurobiology: A critical perspective.

Authors:  Bhaskar Roy; Yogesh Dwivedi
Journal:  Neurosci Biobehav Rev       Date:  2016-11-09       Impact factor: 8.989

2.  Acute changes in cerebral blood flow after single-infusion ketamine in major depression: a pilot study.

Authors:  Sara Gonzalez; Megha Vasavada; Stephanie Njau; Ashish K Sahib; Randall Espinoza; Katherine L Narr; Amber M Leaver
Journal:  Neurol Psychiatry Brain Res       Date:  2020-08-28

3.  Suicide: A Précis!

Authors:  Ahmed Naguy; Hytham Elbadry; Hossam Salem
Journal:  J Family Med Prim Care       Date:  2020-08-25

4.  When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.

Authors:  Jill M Pulley; Rebecca N Jerome; Nicole M Zaleski; Jana K Shirey-Rice; Andrea J Pruijssers; Robert R Lavieri; Somsundaram N Chettiar; Helen M Naylor; David M Aronoff; David A Edwards; Colleen M Niswender; Laura L Dugan; Leslie J Crofford; Gordon R Bernard; Kenneth J Holroyd
Journal:  Assay Drug Dev Technol       Date:  2017-12-01       Impact factor: 1.738

5.  N-Acetylcysteine as a novel rapidly acting anti-suicidal agent: A pilot naturalistic study in the emergency setting.

Authors:  Davinder Hans; Anthony Rengel; Jaspreet Hans; Darryl Bassett; Sean Hood
Journal:  PLoS One       Date:  2022-01-28       Impact factor: 3.240

6.  Antisuicidal efficacy of ketamine infusion in suicidal patients of depressive disorder.

Authors:  Umesh Pathak; Sunil Kumar Ahuja; Rajeev Dwivedi; Nimisha Mishra; Pradeep Kumar; Dheerendra Kumar Mishra; Rajesh Singh
Journal:  Indian J Psychiatry       Date:  2021-10-12       Impact factor: 1.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.